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Abstract
Background: There is no safe, effective human vaccine against brucellosis. Live attenuated Brucella
strains are widely used to vaccinate animals. However these live Brucella vaccines can cause disease
and are unsafe for humans. Killed Brucella or subunit vaccines are not effective in eliciting long term
protection. In this study, we evaluate an approach using a live, non-pathogenic bacteria (E. coli)
genetically engineered to mimic the brucellae pathway of infection and present antigens for an
appropriate cytolitic T cell response.
Methods: E. coli was modified to express invasin of Yersinia and listerialysin O (LLO) of Listeria to
impart the necessary infectivity and antigen releasing traits of the intracellular pathogen, Brucella.
This modified E. coli was considered our vaccine delivery system and was engineered to express
Green Fluorescent Protein (GFP) or Brucella antigens for in vitro and in vivo immunological studies
including cytokine profiling and cytotoxicity assays.
Results: The E. coli vaccine vector was able to infect all cells tested and efficiently deliver
therapeutics to the host cell. Using GFP as antigen, we demonstrate that the E. coli vaccine vector
elicits a Th1 cytokine profile in both primary and secondary immune responses. Additionally, using
this vector to deliver a Brucella antigen, we demonstrate the ability of the E. coli vaccine vector to
induce specific Cytotoxic T Lymphocytes (CTLs).
Conclusion: Protection against most intracellular bacterial pathogens can be obtained mostly
through cell mediated immunity. Data presented here suggest modified E. coli can be used as a
vaccine vector for delivery of antigens and therapeutics mimicking the infection of the pathogen and
inducing cell mediated immunity to that pathogen.
Background
There is no safe, effective human vaccine against brucello-
sis [1]. Brucellosis is a zoonotic disease causing chronic
fatigue, arthritis, recurrent fever, endocarditis, and orchitis
in humans [2,3]. The etiologic agents for brucellosis are
the closely related, facultative, gram-negative, intracellular
coccobacilli, Brucella species [4,5]. The ease with which
Brucella can be transmitted by aerosolization, and the
unpredictable timing of the onset of symptoms raise the
specter of a potentially insidious bioterror attack [6-9].
During the course of infection, Brucella are actively phago-
cytosed by macrophages or other phagocytic cells where
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replicate in endocytic compartments that acquire endo-
plasmic reticulum membranes [10,11]. Bacteremia occurs
during an acute phase that is hard to define or detect
[12,13]. Live attenuated Brucella strains are widely used to
vaccinate animals against brucellosis. However, these live
Brucella vaccines can cause disease and are unsafe for
humans [14-17]. Killed Brucella or subunit vaccines are
not effective in eliciting long term protection [18]. There-
fore, a new vaccine approach is needed.
Eliciting a specific T cell response is necessary to fight Bru-
cella infection. Numerous studies have shown that Th1 or
cell mediated immunity is crucial for protection against
brucellosis [19] however Th2 or humoral immunity also
participates in protecting the host [20-23]. Adoptive trans-
fer of Brucella immune T cells protects mice against viru-
lent Brucella infection [24,25] with both CD4+ and CD8+
T cells involved in immunity [26,27]. Nevertheless,
murine brucellosis is markedly exacerbated in MHC I
knockout mice that lack CD8+ T cells compared to CD4+ T
cell deficient mice or wild type mice [19]. In fact numer-
ous studies have shown that a CTL response is key to effec-
tive Brucella immunity [26,28-30].
Our approach utilizes a non-pathogenic Escherichia coli to
mimic the intracellular pathogen Brucella melitensis in
delivery and presentation of antigens to stimulate a Th1
and CTL response. E. coli are normally extracellular while
Brucella are intracellular bacteria. Therefore, we engi-
neered E. coli (DH5α) to express a plasmid containing the
inv gene from Yersinia pseudotuberculosis and the hly gene
from Listeria monocytogenes [31]. Introduction of inv con-
fers E. coli invasion of host cells by binding the αβ1-
integrin heterodimer. Upon clustering of integrins, inva-
sin activates signaling cascades. One signaling pathway
causes activation of components of focal adhesion com-
plexes including Src, focal adhesion kinase, and cytoskel-
etal proteins, leading to the formation of pseudopods that
engulf the bacteria into the host cell. Binding of invasin to
β1-integrin is necessary and sufficient to induce phagocy-
tosis of the bacteria even by non-professional phagocytic
cells. A second pathway including activation of Rac1, NF-
κB, and mitogen-activated protein kinase, leads to pro-
duction of proinflammatory cytokines [32]. After inter-
nalization, E. coli is taken into the phagosome/lysosome
where lysis of the bacterium occurs. The hly gene product,
along with other bacterial proteins, is release into the lys-
osomal vesicle. The sulfhydryl-activated hly, also known
as listeriolysin O (LLO) is a pore-forming cytolysin capa-
ble of binding and perforating phagosomal membranes at
low pH [33]. The cytoplasmic contents of the bacteria can
then escape into the cytosolic compartment of the mam-
malian cell through the pores generated by LLO. This crit-
ical step exports antigen from the E. coli into the cytosol
where further processing by proteosomes and transloca-
tion by TAP into the endoplasmic reticulum lumen occurs
for MHC class I presentation [34]. LLO is sufficient for
MHC class I presentation of Ag when co-expressed in E.
coli that are phagocytosed by Antigen Presenting Cells
(APC) such as macrophages and dendritic cells [34,35].
Using similar recombinant E. coli, others have shown suc-
cessful delivery of genes and molecules [31,34-44]. In this
study, we investigate the potential of inv-hly expressing
recombinant E. coli as a vaccine vector for immunization
against the intracellular pathogen, Brucella.
Methods
Cell culture
Cells were maintained in RPMI 1640 medium (Invitro-
gen) supplemented with 10% fetal calf serum (FCS), 4.5%
dextrose, 1 mM sodium pyruvate, and antibiotic-antimy-
cotic solution (100 μ/ml penicillin G sodium, 100 μg/ml
streptomycin sulfate, 0.25 μg/ml amphotericin B). In
addition, drugs used for selection were: Blasticidin-S
(Invivogen; 10 μg/ml) and G418-sulfate (Alexis Biochem-
ical; 400 μg/ml). Cell lines included: D17 (ATCC CCL-
183), TB1 (ATCC CCL-88), J774A.1 (ATCC TIB-67), HeLa
S3 (ATCC CCL-2.2), RAW 264.7 (ATCC TIB-71), HEK 293
(ATCC CRL-1573), FLK [45], and the cytotoxicity target
cell line RAW/YFP [45].
Mouse care and vaccination
BALB/c female mice (H-2d), 4–6 wks old were purchased
from Jackson Laboratory and injected with 0.1 ml of PBS
i.p. one day prior to E. coli vaccinations to prevent the
mice from succumbing to LPS-induced endotoxic shock
from live E.coli. Intraperatoneal (i.p.) route of vaccination
was chosen to best deliver live E. coli vector vaccine to
mice based on consistency of results and ease of method.
Recombinant E. coli vaccines were injected i.p. with 2 ×
107 E.coli in PBS. PBS was used for negative controls. For
experiments examining primary immune response
cytokine profiles, mice were injected with E. coli vector
vaccine and after 5 h, euthanized and spleens removed.
For experiments enumerating antigen-specific CD8+ T
cells, RAW264.7 macrophages (H-2d) expressing GFP
(RAW/GFP; [45]) was subjected to gamma-irradation (2
KR) and 1 × 106 cells in PBS were vaccinated in mice i.p.
following the same protocol as the E. coli vaccines. Ani-
mals were boosted with the same dose two weeks later.
Four weeks after the final boost, animals were euthanized
and spleens harvested and processed for CTL assays. Live
imaging was performed (IVIS; Caliper Biosciences, Inc.)
with animals anesthetized using Isofluorane. IVIS image
analysis was performed using Living Image 3.0 software
(Caliper Biosciences). Each group of mice consisted of 4
animals. All animal experiments were conducted with
approval from the Institutional Animal Care and Use
Committee.Page 2 of 14
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The prokaryotic expression vector pGB2Ωinv-hly
[41](10.05 kb; spectinomycin resistance) was a gift from
C. Grillot-Courvalin and expresses invasin from Yersinia
pseudotuberculosis and listeriolysin O (LLO) from Listeria
monocytogenes; pMC221 [46](4.9 kb; chloramphenicol
resistance) expresses uvGFP; pXen-13 (pSK luxCDABE;
8.8 kb; ampicillin resistance) was obtained from Caliper
Life Sciences and carries the luxCDABE operon for engi-
neering bioluminescent Gram-negative bacteria. The
eukaryotic expression vector pEYFP-N1 (4.7 kb; kanamy-
cin resistance) was purchased from Clontech and
expresses enhanced yellow fluorescent protein (EYFP);
pORF-mIL12 (4.8 kb; ampicillin resistance) was pur-
chased from Invivogen and expresses both chains of a
functional murine IL-12 connected by a linker. The retro-
viral vector pLNCX2/EYFP [45](kanamycin/neomycin
resistance) was engineered using pLNCX2 (BD Bio-
sciences) and the EYFP from pEYFP-N1. The retroviral vec-
tor pLNCX2/BMEII1097 was engineered similarly using
the Brucella BMEII1097 gene from pDONR201/
BMEII1097 of the Brucella ORFeome purchased from
OPEN Biosystems [47]. BMEII1097 is a probable tran-
scription regulator syrB. This retroviral vector was used to
transduce Raw 264.7 cells to be used as targets for CTL
assays. The prokaryotic expression vector pDEST17/
BMEII1097 was engineered from pDEST17 (invtrogen)
and pDONR201/BMEII1097.
E. coli vector vaccines
All Escherichia coli used in these studies were strain
DH5α™ (Invitrogen) except for recombinants expressing
pDEST17 vectors were we used BL21-AI™ (Invitrogen).
Table 1 describes the recombinant E. coli vector vaccines.
Invasion and gene delivery assays
One day prior to cell infection, eukaryotic cell lines were
seeded at 2 × 105 cells/well in a six-well plate (or two well
chambered coverslips for fluorescent microscopy) in 2
ml/well RPMI with 10% fetal calf serum (Invitrogen) and
grown in a humidified CO2 incubator at 37°C. E. coli were
grown overnight in a shaking incubator at 37°C in LB
broth (Difco) supplemented with appropriate antibiotic
for plasmid selection. The following day, bacteria were
counted by 600 nm absorbance spectrometry and added
to washed eukaryotic cells in fresh medium without anti-
biotic at the specified MOI. Bacteria were then centrifuged
onto the monolayer at 2 krpm for 5 min at room temper-
ature. Cells were incubated for 90 min, washed and fresh
medium added supplemented with 100 μg/ml gentamicin
to kill extracellular bacteria. For invasion assays, cells were
incubated for an additional 90 min to kill extracellular
bacteria, then washed and lysed in 200 μl of 1% triton X-
100 for 5 min at room temperature. Finally, 800 μl of LB
broth was added to each well and CFU were determined
on LB agar plates supplemented with chloramphenicol,
the selection drug for the GFP plasmid. For gene delivery
assays, cells were incubated then analyzed by fluorescent
microscopy. Random fields of cells were counted and
scored for fluorescence at indicated times. For IL-12
assays, infected cells were fixed and permeabilized using
Cytofix/Cytoperm™ (BD Biosciences) following the man-
ufacturer's protocol. Samples were stained using IL-12
(p40/p70) PE conjugated monoclonal antibody (BD Bio-
sciences) and analyzed by flow cytometry.
MHC class I pentamer staining and cytokine profiling
Pooled splenocytes from four mice per immunization
group were isolated and density gradient purified (Fico/
Lite-LM (Mouse); Atlanta Biologicals). Leukocytes were
subjected to non-T cell depletion using a Pan T Cell Isola-
tion Kit and MACS separation (Miltenyi Biotec) following
the manufacturer's protocol. Aliquots of 2 × 106 T cells
were then used for flow cytometry or cytokine profiling. R-
PE labeled Pro5® MHC class I pentamers GFP antigen spe-
cific for T cell receptors of H-2Kd HYLSTQSAL were co-
stained with FITC labeled rat anti-mouse CD8α and used
for flow cytometry along with controls following the man-
ufacturer's suggested protocol (Proimmune). Controls
included R-PE labeled rat anti-mouse CD3ε (SouthernBi-
Table 1: E. coli vector vaccines
Name Plamid(s)
Invasive E. coli pGB2Ω-inv-hly
E. coli gfp pMC221
E. coli gfp+inv pMC221, pGB2Ω-inv-hly
E. coli gfp+inv+IL12 pMC221, pGB2Ω-inv-hly, pORF-mIL12
E. coli inv+IL12 pGB2Ω-inv-hly, pORF-mIL12
Bioluminescent non-invasive E. coli pXen13™
Bioluminescent invasive E. coli pXen13™, pGB2Ω-inv-hly
E. coli EYFP pEYFP-N1
E. coli inv EYFP pEYFP-N1, pGB2Ω-inv-hly
E. coli inv B7a pGB2Ω-inv-hly, pDEST17-BmeII1097
aAll E. coli used in these studies were DH5a™ except E. coli inv B7 which is strain BL21-AI™.Page 3 of 14
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IgGκ (BD Biosciences). Flow cytometry analysis was per-
formed on 3.5 × 105 cells for each immunization group.
For cytokine profiling, T cells from immunized and con-
trol mice were incubated with gamma-irradiated (2 KR)
RAW 264.7 macrophages on 6 well plates with or without
the addition of 50 mM GFP peptide (HYLSTQSAL; A&A
Labs LLC) for 3 days. Supernatant was harvested, centri-
fuged to remove cell debris and processed using a Th1/
Th2 cytokine kit by cytometric bead array (BD Bio-
sciences). Data acquisition and analysis was performed
according to the manufacturer's instructions using flow
cytometry.
Cell mediated cytotoxicity
Splenocytes from immunized mice were isolated and gra-
dient purified (described above) for use as effector cells.
Transduced RAW 264.7 cells expressing GFP or
BMEII1097 were cloned by limiting dilution and used as
target cells. Cytotoxic effector cells were expanded in vitro
by growth on confluent 2 KR gamma-irradiated target
cells in six-well plates supplemented with 10% T-stim
without Con A (BD Biosciences) for three days. Effector
cells were then washed and purified through a density gra-
dient. Cells were counted and assayed using a CytoTox 96®
Non-Radioactive Cytotoxicity kit (Promega) following the
manufacturer's protocol with 4 h incubation.
Flow cytometry
Acquisition was performed on a FACSCalibur flow cytom-
eter (BD Biosciences) and analyzed using FlowJo 8.7.1
software (Tree Star, Inc).
Cell transfection and transduction
Retrovirus-mediated gene transfer was accomplished
using the BD Retro-X System (BD Biosciences) following
the manufacturer's suggested protocol. Briefly, 100 × 20
mm tissue culture dishes (Falcon) were seeded with the
packaging cell line GP2-293 at 70–90% confluency. GP2-
293 cells were co-transfected with 5 μg each of retroviral
vector and the envelope glycoprotein expression vector
pVSV-G using 15 μl/transfection of Lipofectamine 2000
(Invitrogen) for 3 h in a total volume of 5 ml medium/
dish. Subsequently, transfection medium was replaced
with 10 ml growth medium, and the cells incubated for 72
h. Retrovirus-containing supernatant was harvested, fil-
tered (0.45 μm), and concentrated by ultracentrifugation.
Supernatant was removed and virus resuspended in the
residue (~200 μl) and frozen (-80°C). Cells for transduc-
tion were plated on 6-well tissue culture plates (Falcon) at
50% confluency. Concentrated retrovirus (titer unknown)
along with polybrene (8 μg/ml) were added to 1 ml/well
cells and incubated overnight. Transduction medium was
replaced with fresh growth medium, and the following
day cells were split into appropriate selective medium.
Electron microscopy
Cell lines (2 × 105 cells/well) were incubated on glass cov-
erslips in six-well plates overnight at 37°C in a CO2
humidified incubator. Using conditions as with invasion
assays, invasive or non-invasive E. coli were incubated
with the cells at MOI 100 for 90 min. The cells were thor-
oughly washed to remove extracellular bacteria followed
by gentimycin incubation for an additional 90 min. Cells
were washed in PBS and fixed in Karnovsky's Fixative
(Electron Microscopy Sciences) following manufacturer's
protocol. TEM was performed at the University of Wiscon-
sin Medical School Electron Microscope Facility http://
www.micro.wisc.edu/. Figures were imported using
Adobe Photoshop CS3 10.0.1.
Statistical analysis
Student's t-test was performed and results expressed as the
arithmetic mean with the variance of the mean (mean ±
SE).
Results
The recombinant E. coli vaccine vector efficiently infects 
cells
The objective of this study was to take a non-pathogenic
organism such as Escherichia coli and genetically engineer
it to mimic infectivity and intracellular antigen trafficking
of a pathogen such as Brucella melitensis. The engineered
bacteria would then be employed as a vaccine vector for
Brucella antigen delivery and evaluated for immune
response. E. coli are normally extracellular, and taken up
and destroyed by phagocytic cells such as macrophages.
We transformed GFP expressing E. coli DH5α (E. coli gfp)
with a plasmid encoding invasin from Yersinia pseudotu-
berculosis and LLO from Listeria monocytogenes (E. coli
gfp+inv) and tested whether these E. coli were invasive to
non-professional as well as professional phagocytic cell
lines. Non-invasive E. coli (E. coli-gfp) or invasive E. coli (E.
coli gfp+inv) were added to different cell lines and ana-
lyzed by fluorescent microscopy. Addition of invasive E.
coli to all cell lines, phagocytic and non-phagocytic,
resulted in intracellular fluorescent bacteria. However,
only minimal non-invasive E. coli fluorescence was
observed in non-phagocytic cell lines (D17, FLK, 293,
TB1), but was present in macrophage cell lines (RAW and
J774). An example with TB1 and RAW264.7 cells is shown
in Figure 1. To further determine whether the invasive E.
coli were intracellular, invasion assays were performed
(Table 2). Note non-invasive E. coli were not recovered
unless a high MOI was used. In contrast, large numbers of
invasive E. coli were recovered from all cell lines analyzed.
Furthermore, electron microscopy showed invasive E. coli
bound to the cell surface and engulfed by lamellipodia
consistent with invasin-integrin interactions (Figure 2).
Non-invasive E. coli were also used in the TEM assay, but
could not be detected within or surface-bound to any
non-phagocytic cell line (data not shown).Page 4 of 14
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cine vector, we examined localization and persistence of
the vector in vivo. We transformed lux operon expressing
E. coli DH5α (constitutively bioluminescent) with the
inv-hly encoding plasmid as our invasive E. coli (inv E.
coli). Mice were intraperitoneal injected with non-inva-
sive or invasive bioluminescent E. coli and analyzed by
biophotonic imaging over time. Both bioluminescent spe-
cies trafficked to the spleen. However, the invasive E. coli
vector persisted longer at the site of injection suggesting
an extended period of antigen delivery (Figure 3).
The recombinant E. coli vaccine vector efficiently delivers 
therapeutics
Unlike Escherichia, Brucella, after being engulfed by the
cell, escape phagosome lysis and multiply at the endo-
plasmic reticulum. Most likely, this process leads to MHC
class I presentation of Brucella antigens by the host cell
[48]. Escherichia, in contrast, are phagocytosed and rapidly
destroyed with antigens being presented by MHC class II
[49,50]. Therefore, the inv expressing plasmid co-
expresses hly (hemolysin) to enhance MHC class I presen-
tation of antigens carried by the invasive E. coli vaccine
vector. Hemolysin (hly) or LLO perforates phagosomal
membranes at low pH and the contents of the vaccine are
released into the cytosol of the cell [51]. To test the func-
tionality of the hly gene product in the E. coli vector, we
first examined delivery of a eukaryotic expression plas-
mid, pEYFP-N1 expressing yellow fluorescent protein
(YFP) under control of the eukaryotic CMV promoter,
using fluorescent microscopy. Table 3 shows results after
two or seven days post infection (MOI 100) of confluent
cells lines. Only the LLO expressing E. coli vector trans-
ferred functional YFP plasmid to all mammalian cells
tested. Interestingly, the number of YFP positive cells per
total cells increased as time progressed. Also, two days
Table 2: Intracellular bacterial survival (× 104) per 2 × 105 eukaryotic cells
Cell line
(*Macrophages)
MOI 10 (1.5 h Infection) MOI 100 (1.5 h Infection)
E.coli gfp E.coli gfp+inv E.coli gfp E.coli gfp+inv
D17 0 20 0 320
FLK 0 83 2 168
HEK293 0 46 15 627
TB1 0 2 4 345
J774* 0 18 19 270
RAW* 0 17 11 317
Recombinant invasive E. coli infects phagocytic and non-phagocytic cellsFigure 1
Recombinant invasive E. coli infects phagocytic and non-phagocytic cells. The macrophage cell line, RAW 264.7 and 
epithelial cell line, TB1, were incubated with GFP-expressing E.coli (E. coli gfp) or co-expressing invasin (E. coli gfp+inv) at MOI of 
10 for 3 hours, washed, and after 24 h in gentimicin media, imaged by fluorescent microscopy. The image shows two repre-
sentative fields at equivalent scale of each treatment and cell line.Page 5 of 14
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were observed, but after seven days fluorescent positive
cells were similar to the non-phagocytic cell lines.
Data indicate that the early choice of a Th1 (cellular) or a
Th2 (humoral) immune response is dependent mainly on
the balance between interleukin-12 (IL12), favoring a Th1
response, and interleukin-4 (IL4), favoring a Th2 response
[52,53]. Vaccine studies have demonstrated that co-deliv-
erance of IL12 with the antigen increases Th1 response to
the vaccine [54-57]. Thus, we included a murine IL12
eukaryotic expression plasmid in the invasive E. coli vac-
cine vector and tested for delivery and expression of IL12
in cell culture. Using human HeLa cells, microfluorimetry
analysis demonstrated greater than 70% of E. coli vaccine
infected cells were positive for murine IL12 (Figure 4).
This compared favorably to endogenous murine IL12 pro-
duction by mouse Raw264.7 macrophage cell positive
control. Therefore, the E. coli vaccine vector was effective
in delivering therapeutics to the host.
The recombinant E. coli vaccine vector induces a Th1 
response
Since we were interested in preparing a vaccine that would
stimulate cell mediated immunity, we analyzed for a Th1
cytokine profile and specific CD8+ T cells. Performing real-
time PCR gene expression profiling analysis on spleno-
cytes from mice 5 h following vaccination with invasive E.
coli vaccine or non-invasive E. coli, we analyzed for differ-
ences in primary immune response profiles. This time-
point was chosen because typically, cytokines that pro-
mote T cell responses are measured 5 h post-immuniza-
tion [58]. Table 4 lists fold gene expression from
splenocytes of animals receiving recombinant E. coli vac-
cine compared to control E. coli. The data were difficult to
interpret since both key Th1 and Th2 cytokines were
upregulated in E. coli vaccine immunized animals com-
pared to E. coli control immunized animals. Most likely,
the complexity of the cytokine profile can be attributed to
the highly stimulatory LPS of E. coli [58,59]. Comparison
profiles of E.coli vaccinated animals to PBS control ani-
mals were also performed (data not shown), but the
results were not relevant to our objective of determining
whether the recombinant E. coli vaccine would elicit a dif-
ferent cytokine profile relative to control E. coli.
However, because of the mixed Th1/Th2 cytokine profile
of the primary immune response, we decided to investi-
gate whether the secondary immune response would give
a more defining Th1 cytokine profile response to the anti-
gen. RAW 264.7 macrophages were co-cultured with
splenic T cells from groups of mice that had been immu-
nized 4 weeks. Half of the cultures were supplemented
with the H-2Kd-binding peptide HYLSTQSAL of GFP and
supernatants were measured for cytokines after three days.
GFP nonamer treated cultures showed a large increase in
Th1 cytokine levels in E. coli vaccine immunized T cell
groups with negligible change or decrease in Th2 cytokine
levels (Table 5). Production of IFNγ significantly
increased for the two specific invasive E. coli vaccines,
GFPinv and GFPinvIL12 whereas production of IL4
Transmission Electron Microscopy shows recombinant inva-sive E. coli similarly engulfed by non-professional phagocytic cells (D17, HeLa) and phagoc tic cells (Raw)Figure 2
Transmission Electron Microscopy shows recom-
binant invasive E. coli similarly engulfed by non-pro-
fessional phagocytic cells (D17, HeLa) and phagocytic 
cells (Raw). The osteosarcoma cell line D17, epithelial cell 
line HeLa, and macrophage cell line Raw were incubated with 
recombinant invasive E. coli (MOI 10) for 3 hours, washed, 
fixed and processed for TEM. Image demonstrates each cell 
line engulfing E. coli (arrows) with lamellipodia. Scale bar indi-
cates 2 microns.Page 6 of 14
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()invIL12 as well as significantly increasing in the PBS
control samples. Although the primary response indicated
a mixed Th1/Th2 profile, the secondary immune response
indicates a shift to the Th1 profile. Identification of anti-
gen specific CD8+ T cells would confirm a Th1 profile and
generation of cell-mediated immunity.
To determine the proportion of CD8+ T cells specific for
GFP antigen in the spleens of E. coli vaccine immunized
BALB/c mice, we used H-2Kd MHC class I pentamer com-
plex combined with the GFP peptide HYLSTQSAL (desig-
nated MHC-GFP pentamer) co-stained with CD8+
antibody and analyzed by flow cytometry. As shown in
Figure 5, the invasive E. coli vaccine induced GFP peptide
specific CD8+ T cells at a significant level (p < 0.05) greater
than the non-vaccinated (PBS) and empty vaccine (()inv
IL12; invasive without GFP) controls and at similar levels
to mice given syngeneic APC's constitutively expressing
the antigen (RAW/GFP). However, the non-invasive E. coli
vaccine control (GFP) also induced notable levels of CD8+
T cells not significantly different than the vaccines (GFP
inv and GFP inv IL12). The high number of specific CD8+
T cells induced by the invasive E. coli vaccines correlated
In Vivo biophotonic imaging of mice vaccinated with non-invasive (N) or invasive (Inv) bioluminescent E. coli indicate similar traf-ficking fr m the intraperitoneal site of injection but prolonged antigen expression of the recombinant invasive E. coli vaccineFigure 3
In Vivo biophotonic imaging of mice vaccinated with non-invasive (N) or invasive (Inv) bioluminescent E. coli 
indicate similar trafficking from the intraperitoneal site of injection but prolonged antigen expression of the 
recombinant invasive E. coli vaccine. Mice vaccinated i.p. were anesthetized and imaged at time points indicated. After 80 
min, bioluminescent invasive E. coli were still detectable at the site of injection indicating live bacteria.
Table 3: YFP gene delivery for mammalian cell expression 







2 Days 7 Days 2 Days 7 Days
D17 2 0 67 450
FLK 4 0 74 300
HEK293 4 0 72 360
TB1 0 0 46 150
J774* 0 0 0 400
RAW* 0 0 0 500Page 7 of 14
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ondary immune response by these cells in vitro (Table 5).
As a confirmation of E. coli vaccine generated cell medi-
ated immunity, we analyzed cytolytic T lymphocyte (CTL)
response.
The recombinant E. coli vaccine vector induces specific 
CTL responses
Splenocytes of mice immunized with the invasive E. coli
vaccine vector expressing the GFP antigen were used as
effector cells in cytotoxicity assays against RAW/GFP target
cell lines. As shown in Figure 6, the invasive E. coli vaccine
vectors (GFPinv, GFPinvIL12) elicited marked CTL
response against the target cells versus the control non-
invasive E.coli (GFP) and mock immunized (PBS) mice.
To optimize the immunization protocol, we repeated this
experiment with mice vaccinated with different doses of E.
coli vaccine ranging from 104 to 108 cells in both primary
and booster vaccines. Results (not shown) demonstrated
that the highest vaccine dose (108) elicited the highest
CTL results.
To identify the specificity of the CTL response, an E. coli
vaccine expressing B. melitensis ORF BmeII-1097 (desig-
nated B7) as well as vaccine vector without antigen expres-
sion (designated Empty) was included. Antigen of this
Brucella ORF had been determined by RANKPEP compu-
ter algorithm http://bio.dfci.harvard.edu/RANKPEP/[60]
to have high binding to mouse H-2Kd. BmeII-1097 is a
putative transcriptional regulator with homology to syrB.
Cytotoxicity assays affirmed that CTLs generated by the
invasive E. coli vaccine were specific to the expressed anti-
gen of the vector (Figure 7).
Discussion
There is no safe, effective vaccine against human brucello-
sis. The ability of Brucella to chronically infect humans is
related to its ability to avoid a protective Th1 response
[61-64]. Chronic brucellosis patients display a Th2
immune response [64,65]. Our objective was to analyze a
novel vaccine approach engineering E.coli to mimic inva-
sion, immunoregulation, and antigen expression of Bru-
cella without the pathogenicity of Brucella.
Recombinant invasive E. coli have been used to deliver
therapeutically relevant molecules to mouse and human
professional and non-professional phagocytic cells
[38,66-70]. To date, use of recombinant E. coli as vectors
has mainly been for delivering DNA for genetic vaccina-
tion. The ability to easily be engulfed by cells in addition
to the absence of plasmid size restrictions make bacteria
an interesting vector for gene therapy. In most cases, the
recombinant invasive E. coli is used to efficiently enter
eukaryotic cells where it is destroyed, releasing a eukaryo-
tic vector to the host cell for expression of a therapeutic
gene [66]. Using this basic approach, we modified E. coli
to be a live vaccine that would efficiently invade host cells,
deliver a eukaryotic gene expression vector to help modu-
late the proper immune response, and release a large
amount of antigen efficiently produced by the prokaryotic
expression system. E. coli infection would not be long-
lived, unlike live Brucella, being cleared by the host rela-
tively rapidly. Nevertheless, we found our invasive E. coli
could survive in host cells up to 72 h after infection com-
pared to control E. coli surviving less than 3 h post-infec-
tion (data not shown). These data had been confirmed by
others [41] and suggest an alternate pathway of infection
for our recombinant vaccine E. coli.
Bacteria enter cells through a variety of receptors. Host cell
receptor(s) for binding and internalization of Brucella
have not been identified but involve lipid rafts and com-
Microfluorimetry of supernatant of HeLa cells expressing murine IL12 indicate efficien  plasmid deliv ry afte  infection by ecomb na t inva ive E. coli vaccineFigur  4
Microfluorimetry of supernatant of HeLa cells 
expressing murine IL12 indicate efficient plasmid 
delivery after infection by recombinant invasive E. 
coli vaccine. FACS analysis showed greater than 70% of 
HeLa cells were expressing murine specific IL12 at 72 h after 
3 h infection with the invasive E. coli vaccine. The positive 
control was endogenous IL12 produced by the mouse mac-
rophage cell line RAW 264.7. Negative controls included 
invasive E.coli not carrying the murine IL12 expression vector 
(E. coli BL21 infected HeLa supernatant) and uninfected HeLa 
cells supernatant.Page 8 of 14
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pathway is distinct from the classical endosome-lysosome
pathway in that Brucella inhibit phagosome-lysosome
fusion [10]. Further, smooth Brucella infection of macro-
phages is inefficient with only 40–60% of cells infected in
vitro after 1 hour [72]. In contrast, E. coli are efficiently
engulfed and processed through the classical endosome-
lysosome pathway. However, this leads to rapid destruc-
tion of the bacteria and MHC class II presentation of anti-
gen [73]. To avoid this destructive pathway, we modified
our E. coli vector to express invasin from Yersinia. This
effectively made the vector 80–100% invasive to not only
professional phagocytic cells, but to all cells expressing
β1-integrin (Table 2, Figure 1). Further, the endocytic
pathway was changed as evidenced that live recombinant
E. coli could be isolated from macrophages after 3 hours
(Table 2) whereas wild-type E. coli were destroyed. The
pathway seemed to mimic that of Yersinia as demon-
strated by TEM (Figure 2) where the bacterium adheres to
a filopodium then is internalized to individual endo-
somes [74]. The result is more cells internalizing the vac-
cine with potential to express antigen in association with
MHC class I. Of great interest was the fact that in vivo, the
vaccine expressed the reporter gene (lux) for a prolonged
period at the site of immunization (Figure 3) as only via-
ble bacteria continue to express lux. This confirms broad
cell-type internalization and probable increased antigen
presentation.
In addition to invasin of Yersinia pseudotuberculosis our
recombinant E. coli vaccine vector co-expressed the hly
gene of Listeria monocytogenes on the same vector. Modifi-
cation of the bacterial vaccine to express listeriolysin O
(LLO) was to increase MHC I presentation of the
expressed antigen delivered by the vaccine. As reported by
others [51], the bacteria would be lysed in the phago-
some/lysosome. Through the pore-forming action of LLO,
the cytoplasmic contents of our bacterial vaccine vector
(including the over expressed antigen) would then escape
into the cytosol and thereby be processed by the proteas-
ome. In vitro, this LLO-mediated process has been shown
to improve MHC I presentation of antigens by macro-
Table 4: Immune response gene profile of splenocytes after 5 h immunization with E. coli vaccine.
Gene Fold Regulationa Gene Fold Regulation
Th1 Regulation Csf2 2.07 Th2 Regulation Genes Il10 1.37
Ifna4 5.10 Il13 3.14
Ifng 1.11 Il1f5 -10.20
Il12b 2.38 Il4 1.04
Il16 6.73 Il9 9.25
Il18 -1.04
Il2 1.27 Other Immune Response Genes Ifnb1 -3.36
Il27 -1.11 Il1f10 6.73
Tnf 3.14 Il1rn 4.44
Tnfsf15 11.71 Il21 6.28
Tnfsf4 5.10 Tnfsf8 10.93
Cd40lg 4.44 Tnfsf9 6.28
aValues are real-time PCR expression of recombinant invasive E. coli vaccinated animals relative to expression of non-invasive E. coli vaccinated 
animals. Data were compiled from triplicate wells. T-test p value < 0.001.
Table 5: Three day cytokine production (pg/ml)a of vaccinated mouse splenic T cells cultured in macrophages with (+) or without (-) 50 
μM GFP peptide HYLSTQSAL.
Vaccine Group Th1 Cytokines Th2 Cytokines
TNFα IFNγ IL2 IL4 IL5
(-) (+) (-) (+) (-) (+) (-) (+) (-) (+)
GFP 43.3 179.1 421.6 520.8 0 24 3.2 5.2 51.9 41.5
GFPinv 90.7 348.8 628.9 1353.7 1.9 32.2 4.0 3.8 56.2 10.2
GFPinvIL12 79.5 443.7 349.3 1307.2 22.3 36.7 3.2 0 17.9 5.8
()invIL12 110.8 147.5 673.6 862.9 24.8 3.1 3.0 5.9 71.1 41.4
RAW/GFP 134.7 566.2 NAb NA 10.4 24.8 11.6 0 14.4 0
PBS 127.2 84.5 130.0 440.0 2.2 3 0 12 0 14.1
aValues are from pooled T cells from four mice of each vaccine group. Data are compiled from two experiments. A significant change in expression 
is indicated by 2-fold or greater over non-peptide treated samples (p < 0.05) and is shown in bold text. Decreases are in italics.
bNot enough cells to perform assay.Page 9 of 14
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vaccines expressing LLO induced a very strong anti-tumor
CTL response [43]. We did not confirm improved MHC I
presentation of GFP antigen by LLO in studies presented
here. However, we did see less YFP gene delivery for mam-
malian cell expression using recombinant E. coli without
LLO (Table 3; data not shown). Furthermore, a recent
report demonstrated that the presence of LLO in a recom-
binant bacterial vaccine suppresses CD4+ regulatory T cell
(Treg) inhibition of antigen-specific CD8+ T cell expan-
sion [51]. Primary immune responses activate antigen
induced Tregs limiting vaccine efficacy [75]. The cytokine
profile of the primary immune response to our recom-
binant E.coli vaccine vector revealed a mixed Th1/Th2 pro-
file suggesting a high population of CD4+ T cells and
possibly Tregs (Table 4). However, the secondary immune
response to the vaccine shifted to a Th1 dominant
cytokine profile (Table 5) and subsequent generation of
antigen specific CTLs (Figures 6 and 7). It would be inter-
esting to determine whether LLO expression in our vac-
cine vector affected successful CTL generation and long-
term CD8+ effector memory T cells.
Three major regulatory cytokines, TNFα, IL12, and IFNγ,
were increased in expression relative to controls in both
primary immune response (Table 4) and secondary
immune response (Table 5) using our recombinant E. coli
vaccine vector indicating DC maturation and cell medi-
ated immunity. TNFα is a multipotent proinflammatory
cytokine fundamental for defense against a variety of
intracellular pathogens and is primarily involved in DC
maturation [76,77]. DCs infected with E. coli clearly show
a high capacity to induce the response of naïve T cells, and
TNFα secretion by DCs infected with Brucella as well as E.
FACS analysis of splenic T cells co-stained with anti-CD8 and H-2Kd-GFP peptide pentamer indicate increased numbers of anti-gen specific CTLs in re ombinant invasive E. coli vaccine immunized animalsigur  5
FACS analysis of splenic T cells co-stained with anti-CD8 and H-2Kd-GFP peptide pentamer indicate increased 
numbers of antigen specific CTLs in recombinant invasive E. coli vaccine immunized animals. Groups of four 
mice were vaccinated with GFP-expressing E.coli that were either non-invasive (GFP), recombinant invasive (GFP inv), or recom-
binant invasive with murine IL12 expression vector (GFP inv IL12). Negative controls included recombinant invasive E. coli with 
the murine IL12 expression vector but without the GFP antigen (()inv IL12), and PBS. Positive control vaccine was irradiated 
mouse macrophage RAW cell line (H-2d haplotype) constitutively expressing GFP (Raw/GFP). Vaccinated mice were boosted 
after two weeks, and splenocytes harvested after four weeks.Page 10 of 14
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cells, since TNFα blocking antibodies cause a strong mat-
uration decrease [61]. Invasive E. coli vaccine, similar to
Brucella, initiates the first phase of a T cell dependent
adaptive immune response inducing the secretion of IL12
from APCs. IL12 then potently stimulates IFNγ produc-
tion by activated naïve T cells [78]. Both IL12 and IFNγ are
considered essential for protection against brucellosis
[10]. Our inclusion of a murine IL12 mammalian expres-
sion plasmid in the E. coli vaccine vector results in a high
level of IL12 expression in the infected cell (Figure 4). This
IL12 rich microenvironment surrounding the host anti-
gen presenting cell (professional or non-professional;
Table 2) may be involved in supporting the Th1 profile of
the secondary immune response as indicated by the high
levels of TNFα and IFNγ (Table 5). The resulting matura-
tion of DCs and CD8+ T cells would lead to cell mediated
immunity.
The initial host defense to infection is stimulated by path-
ogen associated molecular patterns (PAMPS) common to
different groups of pathogens. The toll-like receptor (TLR)
family has emerged as a major group of signaling recep-
tors for PAMPs [79,80]. Classical LPS activates macro-
phages and DCs through binding the TLR-4. Nevertheless,
the respective effects of APC stimulation by isolated LPS
or living bacteria are clearly distinct, even when the bacte-
ria carry a highly active LPS like E. coli; the bacteria prob-
ably bind not only to TLR-4 but also to a set of various
receptors. Our studies demonstrate a notable Th1, specific
CTL response to antigen delivered by the invasive, recom-
binant E. coli vaccine vector. However, the highly active
LPS and PAMPS of E. coli may over stimulate the immune
response to the vector. Engineering the E. coli genome to
make the organism less stimulatory to the host would
greatly improve the usefulness of this novel vaccine
approach.
Recombinant E. coli vaccine vector delivering GFP antigen induced higher CTL responseFig re 6
Recombinant E. coli vaccine vector delivering GFP 
antigen induced higher CTL response. Effector spleno-
cytes of mice immunized with E. coli-GFP (GFP), our recom-
binant vaccine vector E. coli-GFP expressing invasin and hly 
(GFPinv), the recombinant vaccine vector also carrying the 
eukaryotic muIL12 vector (GFPinvIL12), or diluent control 
(PBS) were incubated with Raw/GFP target cells and assayed 
for cytotoxicity. Error bars represent quadruplicate wells. 
*GFPinvIL12 generated T cytotoxicity was significantly greater 
than GFP or PBS controls (p < 0.05).
Recombinant invasive E. coli vaccine vector induces specific CTL respo seFigu  7
Recombinant invasive E. coli vaccine vector induces 
specific CTL response. Inv-hly E.coli vaccine vectors 
expressing B. mel ORF BmeII-1097 antigen (B7), GFP antigen 
(GFP), or no antigen (Empty), were used to immunize mice 
along with a negative (PBS) control. Splenocytes were iso-
lated and used against target RAW macrophages expressing 
either GFP (Raw/GFP) or B7 (Raw/B7). Data demonstrate that 
CTLs generated by the E. coli vaccine were specific to antigen 
expressed by the vaccine. *GFP vs GFP and B7 vs B7 specific 
cytotoxicity were significantly greater (p < 0.05) than non-
specific controls.Page 11 of 14
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We began our studies with the goal of developing a live
vaccine vector using an organism (E. coli) that was not
pathogenic to the host and engineering it to mimic the
bacterial pathogen Brucella intracellular infection to stim-
ulate a protective cellular immune response. Our data
show that this vaccine vector could efficiently infect cells
of multiple tissues. These vaccine infected cells acting as
antigen presenting cells can stimulate a cellular immune
response with Th1 cytokine profile and specific CTLs.
Studies are now in progress to determine whether this
recombinant invasive E. coli vaccine vector, expressing
pools of immunodominant Brucella antigens, would be
sufficient to induce a protective immune response in
mice. Our studies show that this novel vaccine could be
applied to any disease where cellular immunity is
required.
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